New antiangiogenetic therapy beyond bevacizumab in the treatment of advanced non small cell lung cancer

Current Pharmaceutical Design

Volumn 21, Issue 32, 2015, Pages 4763-4772

  Sacco, Paola Claudia ^a   Maione, Paolo ^a   Rossi, Antonio ^a   Sgambato, Assunta ^b   Casaluce, Francesca ^b   Palazzolo, Giovanni ^c   Gridelli, Cesare ^a  

^a S G MOSCATI HOSPITAL   (Italy)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

^c ULSS 15 Alta Padovana Cittadella   (Italy)

Author keywords

Angiogenesis; Bevacizumab; Multi target inhibitors; Non small cell lung cancer; Targeted therapy; VEGF

Indexed keywords

AFLIBERCEPT; AXITINIB; BEVACIZUMAB; CEDIRANIB; FIBROBLAST GROWTH FACTOR; LINIFANIB; MOTESANIB; NINTEDANIB; OLARATUMAB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; RAMUCIRUMAB; SORAFENIB; SUNITINIB; VADIMEZAN; VANDETANIB; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADVANCED CANCER; ADVANCED NON SMALL CELL LUNG CANCER; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; HUMAN; MONOTHERAPY; NON SMALL CELL LUNG CANCER; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANTAGONISTS AND INHIBITORS; CARCINOMA, NON-SMALL-CELL LUNG; LUNG NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; PATHOLOGY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; CARCINOMA, NON-SMALL-CELL LUNG; HUMANS; LUNG NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84947966922     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612821666150729120009     Document Type: Review

References (96)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009; 59 (4): 225-49.
2. American Cancer Society. Non small cell lung cancer survival rates by stage. www.cancer.org [Date last updated: July 12, 2013].
3. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012; 23: Suppl 7, vii56-64.
4. Sculier JP, Moro-Sibilot D. First and second-line therapy for advanced non small cell lung cancer. Eur Respir J 2009; 33: 915-30.
5. Folkman J. Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007; 6(4): 273-86.
6. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7(9): 987-9.
7. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407(6801): 249-57.
8. Carmeliet P. VEGF as a key mediator of angiogenesis in cancer. Oncology 2005; 69 (Suppl 3): 4-10.
9. Fontanini G, Lucchi M, Vignati S, et al. Angiogenesis as a prognostic indicator of survival in non-small cell lung carcinoma: a prospective study. J Natl Cancer Inst 1997; 89(12): 881-6.
10. Lucchi M, Fontanini G, Mussi A, et al. Tumor angiogenesis and biologic markers in resected stage I NSCLC. Eur J Cardiothorac Surg 1997; 12(4): 535-41.
11. Macchiarini P, Fontanini G, Dulmet E, et al. Angiogenesis: an indicator of metastasis in non-small cell lung cancer invading the thoracic inlet. Ann Thorac Surg 1994; 57(6): 1534-9.
12. Bremnes RM, Camps C, Sirera R. Angiogenesis in non-small cell lung cancer: the prognostic impact of neoangiogenesis and the cytokines VEGF and bFGF in tumours and blood. Lung Cancer 2006; 51(2): 143-58.
13. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.
14. Imai K, Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 2006; 6: 714-27.
15. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355: 2542-50.
16. Gridelli C, Rossi A, Maione P, et al. Vascular disrupting agents: a novel mechanism of action in the battle against non small cell lung cancer. Oncologist 2009; 14: 612-20.
17. Kerbel RS. Tumor angiogenesis. N Engl J Med 2008; 358(19): 2039-49.
18. Ballas MS, Chachoua A. Rationale for targeting VEGF, FGF, and PDGF for the treatment of NSCLC. Oncol Targets Ther 2011; 4: 43-58.
19. Bergers G, Hanahan D. Modes of resistance to anti-angiogenic therapy. Nat Rev Cancer 2008; 8(8): 592-603.
20. Presta M, Dell'Era P, Mitola S, Moroni E, Ronca R, Rusnati M. Fibroblast growth factor/fibroblast growth factor receptor system in angiogenesis. Cytokine Growth Factor Rev 2005; 16: 159-78.
21. Brooks AN, Kilgour E, Smith PD. Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer. Clin Cancer Res 2012; 18: 1855-62.
22. Underwood PA, Bean PA, Gamble JR. Rate of endothelial expansion is controlled by cell: cell adhesion. Int J Biochem Cell Biol 2002; 34(1): 55-69.
23. Beitz JG, Kim IS, Calabresi P, Frackelton AR. Human microvascular endothelial cells express receptors for platelet-derived growth factor. Proc Natl Acad Sci USA 1991; 88: 2021-5.
24. Wu E, Palmer N, Tian Z, et al. Comprehensive dissection of PDGFPDGFR signaling pathways in PDGFR genetically defined cells. PLoS One 2008; 3: e3794.
25. Abramsson A, Lindblom P, Betsholtz C. Endothelial and non endothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors. J Clin Invest 2003; 112(8): 1142-51.
26. Jenab-Wolcott J, Giantonio BJ. Bevacizumab: current indications and future development for management of solid tumors. Expert Opin Biol Ther 2009; 9(4): 507-17.
27. Sandler A, Gray R, Perry MC, et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006; 355(24): 2542-50.
28. Reck M, von Pawel J, Zatloukal P, et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for non squamous non-small cell lung cancer: AVAil. J Clin Oncol 2009; 27(8): 1227-34.
29. Reck M, von Pawel J, Zatloukal P, et al. Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for non squamous non-small-cell lung cancer: results from a randomized phase III trial (AVAiL). Ann Oncol 2010; 21: 1804-9.
30. Johnson DH, Fehrenbacher L, Novotny WF, et al. Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2004; 22(11): 2184-91.
31. Crino L, Dansin E, Garrido P, et al. Safety and efficacy of first-line bevacizumab-based therapy in advanced non-squamous non-small cell lung cancer (SAiL, MO19390): a phase 4 study. Lancet Oncol 2010; 11(8): 733-40.
32. Fischbach NA, Spigel D, Brahmer J, et al. Preliminary safety and effectiveness of bevacizumab (BV)-based treatment in subpopulations of patients (pts) with non-small cell lung cancer (NSCLC) from the ARIES study: a bevacizumab (BV) treatment observational cohort study (OCS). J Clin Oncol 2009; 27(15S). Abstract 8040.
33. Sandler AB, Schiller JH, Gray R, et al. Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable nonsmall cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab. J Clin Oncol 2009; 27(9): 1405-12.
34. Spratlin JL, Mulder KE, Mackey JR. Ramucirumab (IMC-1121B): a novel attack on angiogenesis. Future Oncol 2010; 6: 1085-94.
35. Spratlin JL, Cohen RB, Eadens M, et al. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol 2010; 28: 780-7.
36. Garon EB, Ciuleanu TE, Arrieta O, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial. Lancet 2014; 384: 665-73.
37. Hainsworth JD, Fang L, Huang JE. BRIDGE: an open-label phase II trial evaluating the safety of bevacizumab + carboplatin/ paclitaxel as first-line treatment for patients with advanced, previously untreated, squamous non-small cell lung cancer. J Thorac Oncol 2011; 6: 109-14.
38. Camidge DR, Berge EM, Doebele RC, et al. A phase II, open-label study of ramucirumab in combination with paclitaxel and carboplatin as first-line therapy in patients with stage IIIB/IV non- small-cell lung cancer. J Thorac Oncol 2014; 9: 1532-9.
39. Eli Lilly and Co. A study of pemetrexed and carboplatin/cisplatin or gemcitabine and carboplatin /cisplatin with or without IMC-1121B in patients previously untreated with recurrent or advanced nonsmall cell lung cancer (NSCLC). Clinical trial identifier number: NCT01160744. http: //clinicaltrials.gov/show/NCT01160744.
40. Loizos N, Xu Y, Huber J, et al. Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target. Mol Cancer Ther 2005; 4(3): 369-79.
41. A study of paclitaxel/carboplatin with or without IMC-3G3 in previously untreated locally advanced or metastatic non-small cell lung cancer (NSCLC). ClinicalTrials.gov Identifier: NCT00918203
42. Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008; 68: 4774-82.
43. Ellis PM, Kaiser R, Zhao Y, Stopfer P, Gyorffy S, Hanna N. Phase I open-label study of continuous treatment with BIBF 1120, a triple angiokinase inhibitor pemetrexed in pretreated non-small cell lung cancer patients. Clin Cancer Res 2010; 16: 2881-9.
44. Reck M, Kaiser R, Eschbach C, et al. A phase II double-blind study to investigate efficacy and safety of two doses of the triple angiokinase inhibitor BIBF 1120 in patients with relapsed advanced non-small-cell lung cancer. Ann Oncol 2011; 22: 1374-81
45. Reck M, Kaiser R, Mellemgaard A, et al. Nintedanib (BIBF 1120) plus docetaxel in NSCLC patients progressing after one prior chemotherapy regimen: results of Lume-Lung 1, a randomized, doubleblind, phase III trial. J Clin Oncol 2013; 31: LBA8011.
46. Hanna NH, Kaiser R, Sullivan RN. Lume-lung 2: a multicenter, randomized, double-blind, phase III study of nintedanib plus pemetrexed versus placebo plus pemetrexed in patients with advanced nonsquamous non-small cell lung cancer (NSCLC) after failure of first-line chemotherapy. J Clin Oncol 2013; 31: 8034.
47. Ciardiello F, Caputo R, Damiano V, et al. Antitumor effects of ZD6474, a small molecule vascular endothelial growth factor receptor tyrosine kinase inhibitor, with additional activity against epidermal growth factor receptor tyrosine kinase. Clin Cancer Res 2003; 9(4): 1546-56
48. Herbst RS, Sun Y, Eberhardt WEE, et al. Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol 2010; 11: 619-26.
49. de Boer RH, Arrieta Ó, Yang CH, et al. Vandetanib plus pemetrexed for the second-line treatment of advanced non-small-cell lung cancer: a randomized, double-blind phase III trial. J Clin Oncol 2011; 29: 1067-74.
50. Natale RB, Thongprasert S, Greco FA, et al. Phase III trial of vandetanib compared with erlotinib in patients with previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 1059-66.
51. Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor: a randomized, double-blind phase III trial (ZEPHYR). J Clin Oncol 2012; 30: 1114-21.
52. Nikolinakos P, Heymach JV. The tyrosine kinase inhibitor cediranib for non-small cell lung cancer and other thoracic malignancies. J Thorac Oncol 2008; 3: 131-4.
53. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor- 2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65: 4389-400.
54. Goss GD, Arnold A, Shepherd FA, et al. Randomized, double-blind trial of carboplatin and paclitaxel with either daily oral cediranib or placebo in advanced non-small-cell lung cancer: NCIC clinical trials group BR24 study. J Clin Oncol 2010; 28: 49-55.
55. Laurie SA, Solomon BJ, Seymour L. A randomized double-blind trial of carboplatin plus paclitaxel (CP) with daily oral cediranib (CED), an inhibitor of vascular endothelial growth factor receptors, or placebo (PLA) in patients (pts) with previously untreated advanced non-small cell lung cancer (NSCLC): NCIC Clinical Trials Group study BR29. J Clin Oncol 2012; 30(Suppl 15): 7511.
56. Dy GK, Mandrekar SJ, Nelson GD, et al. A randomized phase II study of gemcitabine and carboplatin with or without cediranib as first-line therapy in advanced non-small cell lung cancer: North Central Cancer Treatment Group Study N0528. J Thorac Oncol 2013; 8(1): 79-88.
57. Gadgeel SM, Ruckdeschel JC, Wozniak AJ, et al. Cediranib, a VEGF receptor 1, 2, and 3 inhibitor, and pemetrexed in patients (pts) with recurrent non-small cell lung cancer (NSCLC). J Clin Oncol 2011; 29 (Suppl 15): 7564.
58. Iyer R, Fetterly G, Lugade A, Thanavala Y. Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother 2010; 11(11): 1943-55.
59. Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008; 7(10): 3129-40.
60. Scagliotti G, Novello S, von Pawel J, et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced nonsmall- cell lung cancer. J Clin Oncol 2010; 28(11): 1835-42.
61. Gatzemeier U, Eisen T, Santoro A, et al. Sorafenib (S) gemcitabine/ cisplatin (GC) vs. GC alone in the first-line treatment of advanced non-small cell lung cancer (NSCLC): Phase III NSCLC research experience utilizing sorafenib (NEXUS) trial. Ann Oncol 2010; 21(Suppl 8).
62. Spigel DR, Burris HA, Greco FA, Shipley DL, Friedman EK, Waterhouse DM. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer. J Clin Oncol 2011; 29: 2582-9.
63. Paz-Ares L, Hirsh V, Zhang L. Monotherapy administration of sorafenib in patients with non-small cell lung cancer: phase III randomized, double-blind, placebo-controlled MISSION trial. Ann Oncol 2012; 23 (Suppl 9): 33.
64. Molina JR, Dy GK, Foster NR, et al. A randomized phase II study of pemetrexed (PEM) with or without sorafenib (S) as second-line therapy in advanced non-small cell lung cancer (NSCLC) of nonsquamous histology. J Clin Oncol 2011; 29: [Abstract 7513].
65. Sun L, Liang C, Shirazian S, Zhou Y, Miller T, Cui J. Discovery of 5-[5-fluoro-2-oxo-1,2-dihydroindol-(3Z)-ylidenemethyl]-2,4- dimethyl-1H-pyrrole-3-carboxylicacid (2diethylaminoethyl) amide, a novel tyrosine kinase inhibitor targeting vascular endothelial and platelet-derived growth factor receptor tyrosine kinase. J Med Chem 2003; 46: 1116-9
66. Mark A Socinski, Silvia Novello, Julie R Brahmer, et al. Multicenter, phase II trial of sunitinib in previously treated, advanced nonsmall- cell lung cancer. J Clin Oncol 2008; 26: 650-6.
67. S Novello, GV Scagliotti, R Rosell, et al. Phase II study of continuous daily sunitinib dosing in patients previously treated advanced non-small cell lung cancer. Br J Cancer 2009; 101: 1543-8
68. Giorgio V. Scagliotti, Maciej Krzakowski, Aleksandra Szczesna, et al. Sunitinib plus erlotinib versus placebo plus erlotinib in patients with previously treated advanced non-small-cell lung cancer: A Phase III Trial. J Clin Oncol 2012; 30: 2070-8.
69. Heist RS, Wang XF, Hodgson L, et al. CALGB 30704: a randomized phase II study to assess the efficacy of pemetrexed or sunitinib or pemetrexed plus sunitinib in the second-line treatment of advanced non-small cell lung cancer (NSCLC). J Clin Oncol 2012; 30 (Suppl 15): 7513.
70. Socinski MA, Wang XF, Baggstrom MQ, et al. Sunitinib (S) switch maintenance in advanced non-small cell lung cancer (NSCLC): An ALLIANCE (CALGB 30607), randomized, placebo-controlled phase III trial. J Clin Oncol 32: 5s, 2014 (suppl; abstr 8040).
71. Polverino A, Coxon A, Starnes C, Diaz Z, DeMelfi T, Wang L. AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res 2006; 66: 8715-21.
72. Blumenschein GR Jr, Kabbinavar F, Menon H, Mok TS, Stephenson J, Beck JT. Motesanib NSCLC Phase II Study Investigators. A phase II, multicenter, open-label randomized study of motesanib or bevacizumab in combination with paclitaxel and carboplatin for advanced nonsquamous non-small-cell lung cancer. Ann Oncol 2011; 22: 2057-67.
73. Scagliotti GV, Vynnychenko I, Park K, et al. International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1. J Clin Oncol 2012; 30: 2829-36.
74. Kubota K, Ichinose Y, Scagliotti G, et al. Phase III study (MONET1) of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non small-cell lung cancer (NSCLC): Asian subgroup analysis. Ann Oncol 2014; 25: 529-36.
75. Sonpavde G, Hutson TE. Pazopanib: A novel multitargeted tyrosine kinase inhibitor. Curr Oncol Rep 2007; 9: 115-9.
76. Scagliotti V, Felip E, Besse B, et al. An open-label, multicenter, randomized, phase II study of pazopanib in combination with pemetrexed in first-line treatment of patients with advanced-stage non-small-cell lung cancer. J Thoracic Oncol 2013; 8(12): 1529-37.
77. O'Brien. M.E.R, Gaafar R, Hasan B, et al. Double blind randomized phase III study of maintenance pazopanib (PZ) versus placebo (P) in non small cell lung cancer (NSCLC) patients (PTS) non progressive after first line chemotherapy [CT] (EORTC LUNG CANCER GROUP, 08092): MAPPING. Ann Oncol 2014 (Suppl 4): iv426-70.
78. Konduri K, Smith D, Compton N, Lockheed DE, Chakrabarti D, Bhatt K. Phase II study of maintenance therapy with pazopanib or pemetrexed in patients with advanced non-small cell lung cancer (NSCLC) who have not progressed following platinum-based chemotherapy. [abstract]. In: Proceedings of the AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics; 2013 Oct 19-23; Boston, MA. Philadelphia (PA): AACR; Mol Cancer Ther 2013; 12(11 Suppl): Abstract nr C71.
79. Altorki N, Lane ME, Bauer T, et al. Phase II proof-of-concept study of pazopanib monotherapy in treatment-naive patients with stage i/ii resectable non-small-cell lung cancer. J Clin Oncol 2010; 28: 3131- 7.
80. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23: 5474- 83.
81. Schiller JH, Larson T, Ou SH, et al. Efficacy and safety of axitinib in patients with advanced non-small-cell lung cancer: results from a phase II study. J Clin Oncol 2009; 27: 3836-41.
82. Twelves CJ, Chmielowska E, Havel L, et al. Randomised phase II study of axitinib or bevacizumab combined with paclitaxel/ carboplatin as first-line therapy for patients with advanced non-small-cell lung cancer. Ann Oncol 2014; 25: 132-8.
83. Belani CP, Yamamoto N, Bondarenko IM, et al. Randomized phase II study of pemetrexed/cisplatin with or without axitinib for nonsquamous non-small-cell lung cancer. BMC Cancer 2014; 14: 290.
84. Shankar DB, Li J, Tapang P, et al. ABT-869, a multitargeted receptor tyrosine kinase inhibitor: inhibition of FLT3 phosphorylation and signaling in acute myeloid leukemia. Blood 2007; 109: 3400- 08.
85. Eng-Huat T, Glenwood GD, Salgia R, et al. Phase 2 trial of linifanib (ABT-869) in patients with advanced non-small cell lung cancer. J Thoracic Oncol 2011; 6(8): 1418-25.
86. Ramalingam SS, Shtivelband M, Soo RA, et al. Randomized phase II study of carboplatin and paclitaxel with either linifanib or placebo for advanced nonsquamous non-small-cell lung cancer. J Clin Oncol 2015 10; 33(5): 433-41.
87. Dome B, Hendrix MJ, Paku S, Tovari J, Timar J. Alternative vascularization mechanisms in cancer: Pathology and therapeutic implications. Am J Pathol 2007; 170: 1-15.
88. Patterson D M, Rustin G J. Vascular damaging agents. Clin Oncol (R Coll Radiol) 2007; 19: 443-56.
89. McKeage MJ, Von Pawel J, Reck M, et al. Randomised phase II study of ASA404 combined with carboplatin and paclitaxel in previously untreated advanced nonsmall cell lung cancer. Br J Cancer 2008; 99: 2006-12.
90. Antisoma plc. ATTRACT-1 phase III trial of ASA404 halted following interim analysis. Press release. March 29, 2010. http: //www.antisoma.com/asm/media/press/pr2010/2010-03-29/.
91. Antisoma plc. Antisoma announces outcome of ASA404 ATTRACT- 2 trial. Press release. November 11, 2010. http: //www.antisoma.com/asm/media/press/pr2010/2010-11-11/.
92. Ramlau R, Gorbunova V, Ciuleanu TE, et al. Aflibercept and docetaxel versus docetaxel alone after platinum failure in patients with advanced or metastatic non-small-cell lung cancer: a randomized, controlled phase III trial. J Clin Oncol 2012; 30: 3640-7.
93. Dowlati A, Gray R, Sandler AB, Schiller JH, Johnson DH. Cell adhesion molecules, vascular endothelial growth factor, and basic fibroblast growth factor in patients with non-small cell lung cancer treated with chemotherapy with or without bevacizumab-an Eastern Cooperative Oncology Group Study. Clin Cancer Res 2008; 14(5): 1407-12.
94. Hanrahan EO, Lin HY, Kim ES, et al. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol 2010; 28: 193-201.
95. Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010; 28: 949-54.
96. Hurwitz H, Douglas PS, Middleton JP, et al. Analysis of early hypertension (HTN) and clinical outcome with bevacizumab (BV). J Clin Oncol 2010; 28: [Abstract 3039].